泛自閉症障礙治療藥物市場：依藥物類型、年齡層、通路和地區分類

Autism Spectrum Disorder Therapeutics Market, By Drug Type, By Age Group, By Distribution Channel, By Geography

出版日期: 2026年01月29日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026 年泛自閉症障礙治療市場價值為 23.9 億美元，預計到 2033 年將達到 37.61 億美元，2026 年至 2033 年的複合年成長率為 6.7%。

報告內容		報告詳情
基準年：	2025	2026年市場規模：	23.9億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	6.70%	2033 年的預測值：	37.61億美元

自閉症，科學上稱為泛自閉症障礙（ASD），是一種複雜的神經系統疾病，其特徵包括社交技能障礙、重複性行為以及語言和非語言溝通障礙。在ASD治療市場運作的主要企業正致力於進行廣泛的研究、開發和臨床試驗，以推出新藥。例如，2019年2月，施維雅製藥（Servier Laboratories）和NeuroChlore公司宣布啟動一項評估布Bumetanide）治療ASD兒童的3期臨床試驗。Bumetanide通常用於治療體液儲存（水腫）和高血壓。

市場動態

全球泛自閉症障礙（ASD）盛行率的不斷上升預計將推動ASD藥物市場的成長。例如，根據Our World in Data 2017年發布的數據，截至2016年，全球約有6,200萬人患有ASD。此外，其中男性患者不足5000萬。在這6,200萬ASD患者中，約有1,800萬人僅患有自閉症，而4,400萬人患有亞斯伯格症候群或其他頻譜障礙。

然而，監管機構對產品核可和藥品銷售的嚴格規定和持續監督可能會阻礙泛自閉症障礙治療市場的成長。例如，2017年5月，美國食品藥物管理局（FDA）暫停了總部位於路易斯安那州的藥品和營養補充劑生產商Pick and Pay Inc. Cili Minerals的運營，原因是該公司被發現虛假宣傳其產品可以治愈自閉症。

本次調查的主要特點

本報告對泛自閉症障礙治療市場進行了詳細分析，涵蓋了預測期（2019-2027 年）內的市場規模和複合年成長率（%），以 2018 年為基準年。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數介紹了全球泛自閉症障礙治療藥物市場主要企業的概況：公司概況、財務表現、產品系列、地理擴張、分銷策略、關鍵發展和策略。
本報告的研究結果將使企業負責人和經營團隊能夠就未來的產品發布、政府措施、技術升級、市場擴張和行銷策略做出明智的決策。
這份全球泛自閉症障礙治療市場報告對行業內的各種利益相關者都很有用，包括泛自閉症障礙治療市場的投資者、產品製造商、經銷商、相關人員、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

F. Hoffmann-La Roche AG
Neurim Pharmaceuticals, Inc.
Yamo Pharmaceuticals LLC
Servier Laboratories Ltd.
Otsuka Holdings Co. Ltd.
Curemark LLC
Oryzon Genomics SA
GW Pharmaceuticals Plc.
Teva Pharmaceutical Industries Ltd.
Zynerba Pharmaceuticals Inc.
STALICLA SA
Novartis AG
Pfizer, Inc.
Bristol Myers Squibb

第9章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2643

Autism Spectrum Disorder Therapeutics Market is estimated to be valued at USD 2,390 Mn in 2026 and is expected to reach USD 3,761 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,390 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.70%	2033 Value Projection:	USD 3,761 Mn

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study

This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2027, considering 2018 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
- Aripiprazole
- Risperidone
- Melatonin
- CM-AT
- Bumetanide
- Balovaptan
Age Group Insights (Revenue, USD Mn, 2026 - 2033)
- Child
- Adult
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- F. Hoffmann-La Roche AG
- Neurim Pharmaceuticals, Inc.
- Yamo Pharmaceuticals LLC
- Servier Laboratories Ltd.
- Otsuka Holdings Co. Ltd.
- Curemark LLC
- Oryzon Genomics S.A.
- GW Pharmaceuticals Plc.
- Teva Pharmaceutical Industries Ltd.
- Zynerba Pharmaceuticals Inc.
- STALICLA SA
- Novartis AG
- Pfizer, Inc.
- Bristol Myers Squibb

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Autism Spectrum Disorder Therapeutics Market, By Drug Type
- Global Autism Spectrum Disorder Therapeutics Market, By Age Group
- Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel
- Global Autism Spectrum Disorder Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Melatonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
CM-AT
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Bumetanide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Balovaptan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Child
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2020 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Neurim Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Yamo Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Servier Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Curemark LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Oryzon Genomics S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GW Pharmaceuticals Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zynerba Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
STALICLA SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies